Careful consideration of lot size is crucial for multiyear success of a cell therapy business. RoosterBio’s product design and acceleration business works with the company’s customers to help make plans that are appropriate for their stages of product and clinical development. We use the following major considerations in creating a sound multiyear strategy with intermediate milestones:
- Understand what the future looks like and work backward
- Use reasonable to conservative assumptions to estimate a range of needs
- Invest in the right technology platforms.
This special report explains how cell therapy contract services can help biotechnology startups ensure multiyear success. Just fill out the form below to read it now.
Corresponding author Taby Ahsan, PhD, is vice president of analytical, product, and process development, and Jon A. Rowley, PhD, is founder and chief product officer at RoosterBio, 5295 Westview Drive, Suite 275, Frederick, MD 21703; 301-200-5366.